

1 **Running head:** Post-attenuation seizures in dogs with single cEHPSS

2 **Title:** Prognostic factors for short-term survival of dogs that experienced post-attenuation
3 seizures following surgical correction of single congenital extrahepatic portosystemic shunts:
4 93 cases (2005-2018)

5

6 **Authors:**

7 Ronan A. Mullins, MVB¹

8 Carlos Sanchez Villamil, DVM¹

9 Laura E. Selmic, BVetMed (Hons), MPH, DACVS-SA, DECVS²

10 Mickey S. Tivers, BVSc(Hons), PhD, DECVS³

11 J. Brad Case, DVM, MS, DACVS⁴

12 Ameet Singh, BSc, DVM, DVSc, DACVS⁵

13 Kelley M. Thieman Mankin, DVM, MS, DACVS⁶

14 Davina Anderson, MA VetMB, PhD, DSAS(ST), DECVS⁷

15 Robert N. White, BSc(Hons), BVetMed, DSAS(ST), DECVS, SFHEA^{8,9}

16 Kathryn M. Pratschke, MVB, MVM, DECVS¹⁰

17 Hilde de Rooster, DVM, MVM, PhD, DECVS¹¹

18 Anne Kummeling, DVM, PhD, DECVS¹²

19 Donald A. Yool, BVMS, PhD, DECVS, SFHEA¹³

20 Melanie Olive, DVM¹⁴

21 Jean-Philippe Billet, Dr.vét, DECVS¹⁴

22 Ines Gordo, DVM, MS¹⁵

23 Herve Brissot, DEDV, DECVS¹⁵

24 Cameron Broome, BVSc(Hons), DVCS, FANZCVS¹⁰

25 Barbara M. Kirby, DVM, MS, DACVS, DECVS¹

26

27 ¹Section of Veterinary Clinical Sciences, University College Dublin, Belfield, Dublin 4,
28 Ireland.

29 ²Department of Veterinary Clinical Sciences, The Ohio State University, 601 Vernon L Tharp
30 St, Columbus, OH 43210.

31 ³Bristol Veterinary School, University of Bristol, Langford House, Langford, Bristol BS40
32 5DU, UK.

33 ⁴Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University
34 of Florida, Gainesville, FL 32610.

35 ⁵Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Ontario,
36 Canada.

37 ⁶Department of Small Animal Clinical Sciences, College of Veterinary Medicine and
38 Biomedical Sciences, Texas A&M University, College Station, Texas, USA.

39 ⁷Anderson Moores Veterinary Specialists, Poles Lane, Hursley, Winchester SO21 2LL, UK.

40 ⁸Willows Veterinary Centre and Referral Service, Highlands Road, Shirley, Solihull, West
41 Midlands B90 4NH, UK.

42 ⁹School of Veterinary Medicine & Science, University of Nottingham, Sutton Bonington
43 Campus, College Road, Loughborough LE12 5RD, UK.

44 ¹⁰University of Glasgow, School of Veterinary Medicine, 464 Bearsden Rd, Bearsden,
45 Glasgow G61 1QH, UK.

46 ¹¹Small Animal Department, Faculty of Veterinary Medicine, Ghent University, Merelbeke,
47 Belgium.

48 ¹²Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine,
49 Utrecht University, The Netherlands.

50 ¹³The Royal (Dick) School of Veterinary Studies, Easter Bush Campus, Midlothian,
51 Edinburgh EH25 9RG, UK.

52 ¹⁴Centre Hospitalier Vétérinaire Atlantia, 22 Rue René Viviani, 44200 Nantes, France.

53 ¹⁵Pride Veterinary Centre, Riverside Rd, Derby, Derbyshire, DE24 8HX, UK.

54

55 **Corresponding author:** Ronan A. Mullins, Section of Veterinary Clinical Sciences,

56 University College Dublin, Dublin, Ireland. Email: ronan.mullins@ucd.ie

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74 **Abstract**

75 **Objective:** To identify prognostic factors for short-term survival of dogs that experienced
76 seizures within seven days following surgical correction of single congenital extrahepatic
77 portosystemic shunts (cEHPSS).

78 **Study Design:** Multi-institutional retrospective study.

79 **Sample Population:** Ninety-three client-owned dogs.

80 **Methods:** Medical records at 14 veterinary institutions were reviewed to identify dogs that
81 underwent surgical attenuation of a single cEHPSS from January 1st 2005 through February
82 28th 2018 and experienced post-attenuation seizures (PAS) within seven days postoperatively.
83 Logistic regression analysis was performed to identify factors associated with one month
84 survival. Factors investigated included participating institution, signalment, shunt
85 morphology, concurrent/historical conditions, presence of preoperative neurologic signs,
86 presence of preoperative seizures, aspects of preoperative medical management, surgical
87 details including method and degree of shunt attenuation, type of PAS (focal only or
88 generalized +/- focal), drugs administered as part of the treatment of PAS, and development
89 of complications during treatment of PAS.

90 **Results:** Thirty (32.3%) dogs survived to 30 days. Seventy-six (81.7%) dogs experienced
91 generalized PAS. Factors positively associated with short-term survival included having a
92 history of preoperative seizures ($p=0.004$) and development of focal PAS only ($p=0.0003$).
93 The majority of non-survivors were humanely euthanized due to uncontrolled or recurrent
94 seizures.

95 **Conclusions:** Dogs that experienced PAS that had a history of preoperative seizures and
96 those that experienced focal PAS only had significantly improved short-term survival.

97 **Clinical Significance:** The results of this study will help in the counseling of owners who
98 seek treatment for PAS following surgical correction of cEHPSS.

99 **Introduction**

100 Development of post-attenuation seizures (PAS) is a well-recognized complication of surgical
101 correction of portosystemic shunts in dogs,¹⁻²⁵ with often fatal consequences.^{1-3,8-10,12,15,18,21,22}
102 These seizures have an incidence of up to 4.7-8.1% in the recent literature,^{18,21,22,REDACTED} and
103 occur almost exclusively within five days postoperatively.¹⁻²⁵ The etiopathogenesis of PAS is
104 not well understood. Proposed theories include a decline in systemic concentrations of
105 endogenous benzodiazepines/benzodiazepine-like substances, hypoglycemia, electrolyte
106 derangements (hypocalcemia and hypokalemia), hypoxemia, exacerbation of hepatic
107 encephalopathy, an unknown perioperative metabolic event, sudden correction of an adapted
108 to altered metabolic state, systemic hypertension, concurrent brain disease, intraoperative
109 hypotension, and prolonged surgical and anesthetic times.^{2,3,9,10,21,23,26,26} However; none of
110 these has been consistently identified in previous studies.¹⁻²⁵ For instance, PAS have been
111 reported in the face of normal to only mildly elevated ammonia concentrations,^{2,7,9,10,17,20,22} and
112 normal glucose^{7-10,17,20,21,23} and electrolyte concentrations.^{17,20}
113
114 Large-scale studies investigating risk factors for PAS are lacking.²² In a recent study by
115 Strickland et al, increasing age and the presence of hepatic encephalopathy immediately
116 preoperatively were identified as risk factors for postoperative neurologic signs and seizures.²²
117 Occurrence of PAS has not been definitively shown to be associated with shunt morphology
118 (intra- or extrahepatic, or individual sub-morphologies), presence of preoperative seizures, or
119 method or degree of shunt attenuation.^{2,3,6,9,11,14-19,21,22} Certain breeds have been suggested as
120 being at greater risk of PAS including Pugs,^{6,9,23} Maltese terriers,^{1,2} and Jack Russell terriers.¹⁴
121
122 On the basis of a limited number of case reports, small case series and isolated cases within
123 retrospective studies, a guarded prognosis is typically provided following development of

124 PAS.^{1-3,8-10,12,15,18,21,22} The largest published cohort of dogs affected by PAS is in a study by
125 Strickland et al,²² which described 12 dogs with PAS. In that study,²² which included dogs with
126 cEHPSS and cIHPSS, only seven of 12 dogs that experienced PAS survived to discharge. A
127 number of studies; however, have reported a more favorable prognosis.^{7,17,20,21} In one study,²¹
128 dogs that experienced PAS that had a history of preoperative seizures demonstrated improved
129 survival compared with those that had not. There are also reports of a more favorable outcome
130 following treatment of PAS with administration of continuous rate infusion (CRI) of
131 propofol.^{7,17,20} A limitation of these reports; however, is their small size and the fact that other
132 anti-epileptic drugs were administered concurrently with propofol CRI, which makes
133 interpretation difficult.

134

135 The objective of this study was to identify prognostic factors for short-term survival of dogs
136 that experienced PAS within seven days following surgical correction of single cEHPSS. We
137 hypothesized that having received prophylactic LEV, treatment of PAS with propofol CRI,
138 dogs that experienced PAS/underwent surgery in the second half of the study period, and
139 development of focal PAS only would be positively associated with short-term survival.

140

141

142

143

144 **Materials and Methods**

145 **Inclusion and exclusion criteria**

146 Medical records at 14 institutions were retrospectively reviewed to identify
147 dogs that underwent surgical attenuation (suture ligation [SL], thin film banding [TFB], or
148 ameroid ring constrictor [ARC] placement) of a single cEHPSS from January 1st 2005
149 through February 28th 2018 and experienced PAS within seven days postoperatively.

150 Exclusion criteria included dogs with cIHPSS, dogs that did not undergo shunt attenuation
151 due to apparent concurrent portal vein aplasia; and dogs that were lost-to-follow-up prior to
152 30 days postoperatively. Dogs that experienced onset of seizure activity after seven days
153 post-attenuation were excluded.

154

155 **Data collection**

156 Data retrieved from medical records of dogs that met inclusion criteria included breed, age,
157 sex/neuter status, and bodyweight at surgery; year of surgery; shunt morphology (portocaval,
158 portoazygous or portophrenic); concurrent/historical conditions at presentation; presence and
159 type of preoperative neurologic signs and seizures; abnormal preoperative physical
160 examination findings; method of shunt identification (abdominal ultrasound, computed
161 tomography angiography [CTA], magnetic resonance imaging [MRI], intraoperative
162 portovenography [IOPV], nuclear scintigraphy); details of preoperative medical management;
163 prophylactic LEV or other anti-seizure medication(s); method- (SL, TFB or ARC) and degree
164 (complete, partial, or none) of acute intraoperative shunt attenuation; timing and type of PAS
165 (focal only or generalized +/- focal), electrolyte (sodium, potassium and chloride), glucose
166 and ammonia concentrations around time of PAS occurrence; anti-seizure medication(s)
167 administered as part of treatment of PAS; complications experienced during treatment of
168 PAS; and whether the dog survived to one month. Regarding preoperative medical

169 management, dogs were recorded as having received at least one week's duration of
170 preoperative lactulose or not and at least one week's duration of antimicrobial(s) or not.
171 Preoperative diet type was also recorded. Dogs were divided into four groups concerning
172 prophylactic treatment with LEV: received no LEV (LEV-); received LEV at ≥ 20 mg/kg
173 every eight hours (TID) for ≥ 24 hours preoperatively or 60mg/kg intravenous loading dose of
174 LEV perioperatively, and continued at ≥ 20 mg/kg TID postoperatively (LEV1); received LEV
175 at < 20 mg/kg TID, for < 24 hours preoperatively, or continued at < 20 mg/kg TID
176 postoperatively (LEV2); and received LEV postoperatively only (but prior to postoperative
177 seizure activity) according to the same preoperative protocol of group LEV1 (LEV3). Short-
178 term survival was defined as survival to 30 days. For dogs that did not survive to 30 days,
179 whether the dog had died naturally or been humanely euthanized and the cause/reason were
180 recorded. A complication was defined as any unanticipated event that altered the course of
181 PAS treatment.

182

183 **Statistical analyses**

184 Continuous variables were tested for normality using graphical methods, skewness, kurtosis
185 and Shapiro-Wilk tests. Normally and non-normally distributed continuous variables were
186 presented as mean and standard deviation (SD) and median and range, respectively. Categorical
187 variables were presented as frequency and percentages (with 95% CI). Comparison of
188 electrolyte, glucose and ammonia concentrations between survivors and non-survivors and
189 dogs with and without a history of preoperative seizures were made using the independent
190 samples t-test or Mann Whitney U-test depending on normality of the data. Univariable logistic
191 regression analysis was performed to assess for factor association with one month survival.
192 Factors assessed included contributing institution, breed, sex/neuter status, age, and
193 bodyweight at surgery; year of surgery; shunt morphology; presence of preoperative

194 neurological signs; presence of preoperative seizure activity; presence concurrent/historical
195 conditions at presentation; whether the dog received a minimum of one week's duration of
196 preoperative lactulose, whether the dog received a minimum of one week's duration of
197 antimicrobial(s); LEV group (LEV-, LEV1, LEV2 or LEV3); method of shunt attenuation,
198 degree of acute intraoperative shunt attenuation (complete, partial or none); whether the dog
199 developed generalized or focal PAS only, and whether the dog experienced a complication
200 during treatment of PAS. The second half of the study period was defined as January 1st 2012
201 onwards. Additional factors assessed included treatment of PAS with propofol CRI, alfaxalone
202 CRI, benzodiazepine(s), LEV, phenobarbital, potassium bromide, alpha-2 agonist,
203 gabapentin/pregabalin, flumazenil, and mannitol. Multivariable logistic regression analysis
204 was performed to assess all variables identified with $p < 0.2$ in the univariable analysis.
205 Backwards selection was used with a retention alpha of 0.05 for variables to be retained in the
206 model. This allowed calculation of adjusted odds ratios and 95% CI. The statistical analysis
207 was performed using commercially available software.^a Statistical significance was set at
208 $p < 0.05$.

209

210

211

212

213

214

215

216

217

218

219

220 **Results**

221 Ninety-three dogs were included in the study. Details of 75 dogs are the subject of another
222 report.^{REDACTED} Details of 16 dogs have partially been reported previously.^{17,18,20,21}

223

224 **Signalment**

225 Breeds included mixed breed (n=18), Yorkshire terrier (n=15), Bichon Frise (n=12), Pug
226 (n=9), Shih Tzu (n=8), Maltese terrier (n=6), Jack Russell terrier (n=6), Miniature Schnauzer
227 (n=5), Chihuahua (n=4), Dachshund (n=3), West Highland white terrier (n=2), and one each
228 of Norfolk terrier, Border terrier, Brussels Griffon, Coton De Tulear and Setter. There were
229 31 (33.3%) spayed females, 13 (14.0%) intact females, two (2.2%) unspecified females, 28
230 (30.1%) castrated males, and 19 (20.4%) intact males. Median (range) age was 34 (5-124)
231 months. Median (range) weight was 6 (1.4-21.0) kg.

232

233 **Year of surgery**

234 Thirty-three (35.5%) dogs experienced PAS from January 2005 through December 2011 (first
235 half of study period), 60 (64.5%) experienced PAS from January 2012 through February 2018.

236

237 **Historical neurologic signs and seizures**

238 Preoperative neurologic signs were recorded in 73/93 (78.5%) dogs. Preoperative seizures
239 were recorded in 16/93 (17.2%) dogs. The most common neurologic signs included reduced
240 mentation (n=46), pacing/wandering/compulsive walking (n=15), ataxia (n=12), abnormal
241 behavior/behavior change (n=11), head pressing (n=9), hypersalivation/drooling (n=9),
242 circling (n=8), disorientation (n=5), and four each of increased/inappropriate sleeping/sleepy,
243 apparent blindness, and weakness.

244

245 **Concurrent/historical conditions at presentation**

246 Concurrent/historical conditions at presentation were recorded in 27/93 (29.0%) dogs and
247 most commonly included urolithiasis (n=19); urinary tract infection (n=8); cardiac murmur
248 (n=4); unspecified brachycephalic airway syndrome; and one each of urinary
249 sediment/crystalluria, pattern baldness, distichiasis, and cryptorchidism. Two dogs had
250 previously undergone cEHPSS attenuation, seven and 16 months prior, respectively, but did
251 not experience PAS following initial surgery.

252

253 **Method of shunt identification and morphology**

254 Shunts were identified preoperatively by ultrasonography (n=75), CTA (n=31), nuclear
255 scintigraphy (n=3), and/or MRI (n=1). Seventeen dogs underwent IOPV. Shunt morphology
256 was available for 89/93 (95.7%) dogs and included portocaval (n=67), portoazygous (n=16),
257 and portophrenic (n=6).

258

259 **Preoperative medical management**

260 Ninety-one (97.8%) dogs received preoperative medical management, which included
261 combinations of antimicrobial(s), lactulose and a protein-restricted diet. One dog did not
262 receive preoperative medical management. For the remaining dog, this information could not
263 be confirmed. Seventy-eight (83.9%) dogs received at least one week of preoperative
264 antimicrobial. Eighty-one (87.1%) dogs received at least one week of preoperative lactulose.
265 Fifty-seven dogs received a prescription hepatic diet, eight received an unspecified protein-
266 restricted diet, five received a protein-restricted renal diet. Other diets included a
267 hypoallergenic diet (n=3), vegetarian diet (n=2), homemade protein-restricted diet (n=2), and
268 one each received a gastrointestinal diet and homemade chicken and vegetable diet. For the
269 remaining dogs, the type of diet was not recorded.

270

271 **Prophylactic LEV or other anti-seizure medication(s)**

272 Fifty (53.8%) dogs had received prophylactic LEV. One of these dogs had received
273 additional prophylactic treatment with phenobarbital (3 mg/kg every 12 hours) and potassium
274 bromide (8 mg/kg every 24 hours) for 3 months preoperatively. Forty-three (46.2%), 22
275 (23.7%), 25 (26.9%) and three (3.2%) dogs were included in groups LEV-, LEV1, LEV2 and
276 LEV3, respectively.

277

278 **Preoperative physical examination findings**

279 Preoperative physical examination findings were available for 86/93 (92.5%) dogs. Abnormal
280 findings were recorded in 48/86 (55.8%) dogs and most commonly included reduced/altered
281 mentation/lethargy (n=22), underweight/suboptimal body condition (n=16), small stature
282 (n=7), ataxia (n=6), circling (n=4), pacing/wandering (n=3), and cardiac murmur (n=3).

283

284 **Method and degree of shunt attenuation**

285 Shunts were attenuated using TFB (n=36, partial attenuation [n=20], no attenuation [n=16]);
286 ARC (n=33, no attenuation [n=33]); SL (n=23, complete attenuation [n=20]; partial
287 attenuation [n=3]); and combination of TFB and suture (n=1, partial attenuation [n=1]).

288

289 **Type and timing of post-attenuation seizures**

290 Seventy-six (81.7%) dogs were recorded as having developed generalized PAS, while 17
291 (18.3%) developed focal PAS only. Of the 76 dogs that experienced generalized PAS, 13
292 (17.1%) were recorded as having experienced focal PAS that later progressed to generalized
293 despite treatment. Post-attenuation seizures commenced after a median (range) of 48 (3-144)
294 hours postoperatively. Seventy-three (78.5%) dogs developed PAS while hospitalized.
295 Twenty (21.5%) dogs displayed neurologic signs/commenced seizure activity post-discharge.

296

297 **Electrolyte, glucose and ammonia concentrations at the time of post-attenuation**

298 **seizures**

299 Electrolyte, glucose and ammonia concentrations overall (when available), among survivors
300 and non-survivors, and dogs with and without a history of preoperative seizures are listed in
301 Table 1. No significant differences in these parameters were identified between survivors
302 versus non-survivors or dogs with versus without a preoperative history of seizures (Table 1).

303

304 **Treatment of post-attenuation seizures**

305 Ninety (96.8%) dogs received treatment for PAS. One dog that experienced focal PAS only
306 did not receive any anti-seizure treatment. A further dog that experienced focal PAS only did
307 not receive any additional treatment apart from continued administration of LEV. One dog
308 that experienced a generalized seizure at home was already receiving LEV but did not receive

309 any additional treatment. Specific details of drugs administered as part of the treatment of
310 PAS were available for all but one dog. One dog that was receiving prophylactic LEV
311 experienced generalized PAS treated by the primary veterinarian. Specific details regarding
312 additional anti-seizure medication(s) administered were not available. Of 20 (21.5%) dogs
313 that commenced seizure activity post-discharge, nine (45.0%; 9.7% of all dogs) were treated
314 for PAS by their local veterinarian; eight (40.0%; 8.6% of all dogs) were re-presented to the
315 participating institution; two (10.0%) were treated initially by the local veterinarian and
316 subsequently re-presented; while the remaining dog was treated for generalized PAS with
317 continued administration of LEV by the owner at home.

318

319 **Focal seizures only**

320 Dogs that experienced focal PAS only were treated with LEV (n=15; ten were already
321 receiving prophylactic LEV; LEV1 [n=6], LEV2 [n=4]), benzodiazepine(s) (n=9), propofol
322 CRI (n=6), phenobarbital (n=6), potassium bromide (n=3), flumazenil (n=2), alpha-2 agonist
323 (n=1), and/or gabapentin (n=1). One dog was taken back to surgery to have the thin film band
324 removed due to concerns over possible portal hypertension; moderate liver congestion was
325 noted at surgery but without congestion of mesenteric vessels. The dog was euthanized
326 intraoperatively at the request of the owners.

327

328 **Generalized seizures**

329 Dogs that experienced generalized PAS were treated with LEV (n=49; 34 were already
330 receiving prophylactic LEV; LEV1 [n=16], LEV2 [n=21], LEV3 [n=3]), phenobarbital
331 (n=49; one dog was already receiving prophylactic phenobarbital), propofol CRI (n=43),
332 benzodiazepine(s) (n=36), mannitol (n=16), potassium bromide (n=10; one dog was already

333 receiving prophylactic potassium bromide), alpha-2 agonist (n=7), alfaxalone CRI (n=3),
334 and/or gabapentin/pregabalin (n=3).

335

336 **Development of complications during treatment of post-attenuation seizures**

337 Sixteen (17.2%) dogs experienced one or more significant complication(s) during treatment
338 of PAS within 30 days postoperatively (Table 5). The most common complication was
339 development of aspiration pneumonia.

340

341 **Short-term survival**

342 Thirty (32.3%) dogs survived to 30 days. Of those that did not survive, 50 (79.4%) were
343 humanely euthanized, nine (14.3%) died, one (1.6%) suffered cardiorespiratory arrest and
344 was successfully resuscitated but later euthanized. For the remaining three (4.8%) dogs, it
345 was not recorded whether they had died or been euthanized. The most common reason for
346 euthanasia was uncontrolled or recurrent seizures (Table 5). Median (range) survival time of
347 non-survivors was 4 (1-20) days (recorded as 2-3 weeks postoperatively [n=1]). Of those that
348 survived to 30 days, 16 experienced generalized PAS, 14 experienced focal PAS only. Sixty
349 dogs that did not survive to 30 days experienced generalized PAS, while three experienced
350 focal PAS only. Cause of natural death and reasons for humane euthanasia are listed in Table
351 5.

352

353 **Prognostic factors associated with short-term survival**

354 Results of univariable analysis are summarized in Tables 2 and 3. Prophylactic treatment with
355 LEV, surgery performed in the second half of the study period, and treatment of PAS with
356 propofol CRI were not associated with short-term survival. Factors associated with short-term
357 survival in the multivariable analysis included having a history of preoperative seizures

358 (p=0.004) and type of PAS (p=0.0003) (Table 4). Dogs with a history of preoperative
359 seizures had a 7.6-fold (95% CI: 1.9-30.3) increased odds of survival to 30 days compared
360 with those without, with adjustment for PAS type. Dogs that developed focal PAS only had
361 significantly increased odds of survival (OR=14.4 (95% CI: 3.4-60.2)) compared with those
362 that experienced generalized PAS, with adjustment for preoperative seizure activity.

363

364

365

366

367 **Discussion**

368 The main findings of this study are: (1) affected dogs that had a history of preoperative seizures
369 and those that experienced focal PAS only had significantly increased odds of survival to 30
370 days, and (2) having received prophylactic treatment with LEV, treatment of PAS with
371 propofol CRI, and having undergone surgery/experienced PAS in the second half of the study
372 period were not associated with improved short-term survival.

373

374 In a recent study by Brunson et al,²¹ dogs that experienced PAS that had a history of
375 preoperative seizure activity had a 7-fold increased probability of survival compared with those
376 that had not. Similarly, in our study, such dogs had an almost 8-fold increased odds of survival
377 to 30 days. One possible explanation for this is that PAS experienced by both of these subsets
378 of dogs have a different etiopathogenesis or that some dogs with a history of preoperative
379 seizure activity have continuation of these seizures postoperatively. We did not find support
380 for hyperammonemia to be responsible for PAS in such affected dogs in our study, which is
381 consistent with reports by several other investigators.^{2,7,9,10,17,20,22} It is well recognized that
382 ammonia concentrations and severity of encephalopathy do not always correlate, emphasizing
383 the importance of other neurotoxic substances.²⁷ In a study by Strickland et al,²² the presence
384 of hepatic encephalopathy immediately preoperatively was identified as a risk factor for PAS;
385 however, similar to our results, postoperative ammonia concentrations were normal to mildly
386 elevated in all dogs for whom it was available.

387

388 Dogs that experienced focal PAS only in our study had 14.4-fold increased odds of short-term
389 survival compared with those that experienced generalized PAS. Whether focal PAS in such
390 affected dogs represent a less aggressive form of neurologic dysfunction, has a different
391 etiopathogenesis, or would have progressed to generalized PAS without anti-seizure treatment

392 is unknown. Seventeen percent of dogs that developed generalized PAS in our study were
393 recorded as having experienced initial focal PAS, which highlights that these may be a
394 precursor to generalized PAS in some cases. In a study by Mehl et al,¹⁵ all dogs that experienced
395 focal PAS only survived to discharge, while all those that experienced generalized PAS within
396 seven days postoperatively died during hospitalization. The majority of dogs that failed to
397 survive to 30 days in our study were humanely euthanized, most commonly due to uncontrolled
398 or recurrent seizures (Table 5). It is possible that factors such as client unwillingness to continue
399 treatment, financial constraints, or an attending clinician's perception of a poor prognosis for
400 neurologic recovery may have significantly influenced the decision to euthanize. It may be
401 anticipated that generalized PAS may be more challenging to abolish, more distressing for the
402 pet owner to observe, associated with a greater treatment cost and the perception of a poorer
403 prognosis for recovery, all of which may provoke a decision to euthanize.

404

405 Only one third of dogs that experienced PAS in our study survived to 30 days, which is in
406 agreement with previous reports of 0-53.8% in the literature.^{2,3,9,15,18,21,22} The large proportion
407 (81.7%) of dogs in our study that experienced generalized PAS will have strongly influenced
408 the low short-term survival rate as such dogs had significantly decreased odds of survival in
409 the multivariable analysis.

410

411 We hypothesized that having undergone surgery/experienced PAS in the second half of the
412 study period would be positively associated with short-term survival. This was based on the
413 premise that with greater experience in treating PAS and advances in critical care medicine,
414 short-term survival would be improved. This was not supported by the results of our study.
415 Possible explanations for this may be related to factors such as a perceived poor prognosis for
416 neurologic recovery, factors outside of the control of the attending clinician including client

417 unwillingness to pursue treatment and financial constraints, and the overall infrequent
418 occurrence of PAS. In our study, the maximum number of cases of PAS seen by any institution
419 in a single year was four, with most institutions seeing a maximum of one to two cases per
420 year.

421

422 Administration of several anti-epileptic drugs has been described for the treatment of PAS in
423 previous reports including benzodiazepines,^{2,3,9-12,14,15} barbiturates,^{2,3,6-12,14,15} and
424 propofol.^{7,10,14,17} There are; however, no large-scale studies which compare outcomes of
425 affected dogs treated with various anti-epileptic drugs, likely due to the infrequent occurrence
426 of these seizures and subsequent small case numbers within individual institutions.²² In our
427 study, none of these anti-epileptic drugs, including propofol CRI, was associated with short-
428 term survival. On the basis of its non-prospective nature, treatment of PAS with propofol CRI
429 was not randomized in our study. Therefore, it is likely that it will have been administered to
430 the most severely affected cases in our study. While there are reports of a more favorable
431 prognosis with administration of propofol CRI,^{7,17,20} individual numbers are small and may
432 represent a positive outcome publication bias. Previous studies have reported conflicting results
433 regarding the possible protective effect of LEV against development of PAS.^{18,21,22,REDACTED}
434 Approximately half of the dogs in our study received prophylactic LEV. The recommended
435 dose of LEV is 20 mg/kg *per os* every eight hours for a minimum of 24 hours preoperatively.²⁷
436 On the basis of the known pharmacokinetics of the drug (albeit in healthy dogs), continuation
437 of the drug at the same dose during the first seven days postoperatively should be considered.²⁸
438 Several dogs in our study received less standardized protocols of LEV (groups LEV2 and
439 LEV3). No group; however, was of prognostic significance. It is possible that dogs that develop
440 PAS despite receiving prophylactic treatment with LEV are biased toward more severe post-
441 attenuation neurologic dysfunction, although this is purely speculative. It also raises the

442 question whether continued treatment of such dogs with LEV following development of PAS
443 is likely to be of benefit.

444

445 This study has a number of important limitations. Like all retrospective studies, the accuracy
446 of the presented data relies on the completeness of the medical records. Seventy-five of the
447 dogs of the present report are the subject of another study which investigated the effect of
448 prophylactic treatment with LEV on the incidence of PAS in dogs that underwent cEHPSS
449 attenuation.^{REDACTED} On the basis of the infrequent occurrence of PAS, the present study
450 would not have been possible without the inclusion of such dogs. This was a multicenter
451 study involving multiple surgeons, with differences in case management and experience in
452 treating PAS. Treatment of PAS with different anti-epileptic drugs was not randomized but
453 rather based on clinician preference. Drug dosages and infusion dose rates were not
454 standardized. We did not record individual doses of various anti-epileptic drugs used to treat
455 PAS as these will have varied widely even within individual dogs, with most dogs receiving
456 numerous boluses of individual drugs along with variable rates of CRIs. Other factors
457 including the attending clinician's perception of prognosis for neurologic recovery following
458 development of PAS, the extent to which the seizures were treated, cost of treatment and
459 client willingness to treat seizures cannot be controlled due to the retrospective nature of the
460 study. The authors acknowledge that several of the dogs included in this study may have
461 experienced prodromal neurologic signs prior to seizure onset; however, due to its
462 retrospective nature, the exact timing and details of such may not have been accurately
463 recorded in the medical record. The classification of seizures as focal or generalized in this
464 study reflects what was recorded in the medical record. Assignment of a dog as having
465 experienced a seizure will have been based on the attending clinician's/criticalist's
466 interpretation of the neurologic signs manifested. Importantly; however, all dogs were treated

467 at academic teaching hospitals or referral institutions, by multidisciplinary staff with
468 extensive experience in treating dogs with portosystemic shunts and their complications.
469 Finally, just under 10% of dogs that experienced PAS in this study were not treated for PAS
470 at the operating institution and the impact of this on the survival of such dogs is unknown.

471

472 The overall short-term survival rate in this study was low, with just under one third of dogs
473 surviving to 30 days. Affected dogs that had a history of preoperative seizures or experienced
474 focal PAS only had significantly improved short-term survival. The results of this study will
475 help in the counseling of owners who seek treatment for cEHPSS and may serve as a basis
476 for further investigation regarding prevention or treatment of PAS in the future.

477

478

479

480 **Disclosure Statement**

481 The authors report no conflict of interest.

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505 **References**

- 506 1. Mathews K, Gofton N. Congenital extrahepatic portosystemic shunt occlusion in the
507 dog: gross observations during surgical correction. *J Am Anim Hosp Assoc.*
508 1988;24:387-394.
- 509 2. Matushek KJ, Bjorling D, Mathews K. Generalized motor seizures after portosystemic
510 shunt ligation in dogs: five cases (1981-1988). *J Am Vet Med Assoc.* 1990;196:2014-
511 2017.
- 512 3. Hardie EM, Kornegay JN, Cullen JM, et al. Status epilepticus after ligation of
513 portosystemic shunts. *Vet Surg.* 1990;19:412-417.
- 514 4. Komtebedde J, Forsyth SF, Breznock EM, et al. Intrahepatic portosystemic venous
515 anomaly in the dog: perioperative management and complications. *Vet Surg.*
516 1991;20:37-42.
- 517 5. White RN, Burton CA, McEvoy FJ. Surgical treatment of intrahepatic portosystemic
518 shunts in 45 dogs. *Vet Rec.* 1998;142(14):358-365.
- 519 6. Youmans KR, Hunt GB. Cellophane banding for the gradual attenuation of single
520 extrahepatic portosystemic shunts in eleven dogs. *Aust Vet J.* 1998;76(8):531-537.
- 521 7. Heldmann ED, Holt E, Brockman DJ, et al. Use of propofol to manage seizure activity
522 after surgical treatment of portosystemic shunts. *J Small Anim Pract.* 1999;40:590-594.
- 523 8. Hunt GB, Hughes J. Outcomes after extrahepatic portosystemic shunt ligation in 49
524 dogs. *Aust Vet J.* 1999;77:303-307.
- 525 9. Tisdall PL, Hunt GB, Youmans KR, et al. Neurological dysfunction in dogs following
526 attenuation of congenital extrahepatic portosystemic shunts. *J Small Anim Pract.*
527 2000;41(12):539-546.
- 528 10. Yool DA, Kirby BM. Neurological dysfunction in three dogs and one cat following
529 attenuation of intrahepatic portosystemic shunts. *J Small Anim Pract.* 2002;43:171-176.

- 530 11. Connery NA, McAllister H, Skelly C, et al. Cellophane banding of congenital
531 intrahepatic portosystemic shunts in two Irish wolfhounds. *J Small Anim Pract.* 2002;4:
532 345-349.
- 533 12. Hurn SD, Edwards GA. Perioperative outcomes after three different single extrahepatic
534 portosystemic shunt attenuation techniques in dogs: partial ligation, complete ligation
535 and ameroid constrictor placement. *Aust Vet J.* 2003;81(11):666-670.
- 536 13. Kummeling A, Van Sluijs FJ, Rothuizen J, et al. Prognostic implications of the degree
537 of shunt narrowing and of the portal vein diameter in dogs with congenital
538 portosystemic shunts. *Vet Surg.* 2004;33:17-24.
- 539 14. Hunt GB, Kummeling A, Tisdall PL, et al. Outcomes of cellophane banding for
540 congenital portosystemic shunts in 106 dogs and 5 cats. *Vet Surg.* 2004;33:25-31.
- 541 15. Mehl M, Kyles AE, Hardie EM, et al. Evaluation of ameroid ring constrictors for
542 treatment for single extrahepatic portosystemic shunts in dogs: 168 cases (1995-2001).
543 *J Am Vet Med Assoc.* 2005;226:2020-2030.
- 544 16. Mehl ML, Hardie AE, Case JB, et al. Surgical Management of Left-Divisional
545 Intrahepatic Portosystemic Shunts: Outcome After Partial Ligation of, or Ameroid Ring
546 Constrictor Placement on, the Left Hepatic Vein in Twenty-Eight Dogs (1995-2005).
547 *Vet Surg.* 2007;36:21-30.
- 548 17. Gommeren K, Claeys S, de Rooster H, et al. Outcome from status epilepticus after
549 portosystemic shunt attenuation in 3 dogs treated with propofol and phenobarbital. *J*
550 *Vet Emerg Crit Care (San Antonio).* 2010;20(3):346-351.
- 551 18. Fryer KJ, Levine JM, Peycke LE, et al. Incidence of postoperative seizures with and
552 without levetiracetam pretreatment in dogs undergoing portosystemic shunt
553 attenuation. *J Vet Intern Med.* 2011;25:1379-1384.

- 554 19. Weisse C, Berent AC, Todd K, et al. Endovascular evaluation and treatment of
555 intrahepatic portosystemic shunts in dogs: 100 cases (2001-2011). *J Am Vet Med Assoc.*
556 2014;244(1):78-94.
- 557 20. Heidenreich DC, Giordano P, Kirby BM. Successful treatment of refractory seizures
558 with phenobarbital, propofol, and medetomidine following congenital portosystemic
559 shunt ligation in a dog. *J Vet Emerg Crit Care (San Antonio)*. 2016;26(6):831-836.
- 560 21. Brunson BW, Case JB, Ellison GW, et al. Evaluation of surgical outcome,
561 complications, and mortality in dogs undergoing preoperative computed tomography
562 angiography for diagnosis of an extrahepatic portosystemic shunt: 124 cases (2005-
563 2014). *Can Vet J*. 2016;57:59-64.
- 564 22. Strickland R, Tivers MS, Adamantos SE, et al. Incidence and risk factors for
565 neurological signs after attenuation of single congenital portosystemic shunts in 253
566 dogs. *Vet Surg*. 2018;47(6):745-755.
- 567 23. Wallace ML, MacPhail CM, Monnet E. Incidence of Postoperative Neurologic
568 Complications in Pugs Following Portosystemic Shunt Attenuation Surgery. *J Am Anim*
569 *Hosp Assoc*. 2018;54(1):46-49.
- 570 24. Torisu S, Washizu M, Hasegawa D, et al. Sustained severe hypoglycaemia during
571 surgery as a genesis of global brain damage in post ligation seizure of congenital
572 portosystemic shunts dogs. *J Vet Intern Med*. 2006;20(3)753.
- 573 25. Case JB, Marvel SJ, Stiles MC, et al. Outcomes of cellophane banding or percutaneous
574 transvenous coil embolization of canine intrahepatic portosystemic shunts. *Vet Surg*.
575 2018;47(S1):O59-O66.
- 576 26. Aronson LR, Gacad RC, Kaminsky K, et al. Endogenous benzodiazepine activity
577 in the peripheral and portal blood of dogs with congenital portosystemic shunts. *Vet*
578 *Surg*. 1997;26:189-194.

- 579 27. Berent and Tobias. Hepatic Vascular Anomalies. In: Johnston SA, Tobias KM, eds.
580 Veterinary Surgery: Small Animal 2nd edition. St. Louis: Elsevier Saunders, 2018:
581 1852-1886.
- 582 28. Moore S, Munana KR, Papich MG, et al. Levetiracetam pharmacokinetics in healthy
583 dogs following oral administration of single and multiple doses. Am J Vet Res.
584 2010;71:337–341.
- 585

586 **Footnotes**

587 ^aSAS version 9.4, SAS institute, Cary, NC.

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611 **Table 1:** Electrolyte, ammonia and glucose concentrations of all affected dogs (with results
612 available), survivors and non-survivors, and dogs with and without a history of preoperative
613 seizures.

614 **Abbreviations:** SD; standard deviation.

Parameter	Overall (n=93)	Survivors (n=30)	Non- survivors (n=63)	P-value	History of preoperative seizure activity (n=16)	No history of preoperative seizure activity (n=77)	P-value
Sodium Median (range)	143.5 (135.1- 171.0) (n=44) Recorded as normal (n=3)	144.0 (137.0- 155.0) (n=17)	142.5 (135.1- 171.0) (n=27)	0.81	144.4 (137- 151.4) (n=11)	143.0 (135.1- 171.0) (n=33)	0.44
Potassium Mean (\pmSD)	4.0 (\pm 0.4) (n=44) Recorded as	4.1 (\pm 0.5) (n=17)	4.0 (\pm 0.4) (n=27)	0.69	4.1 (\pm 0.7) (n=11)	4.0 (\pm 0.3) (n=33)	0.82

	normal (n=3)						
Chloride	114.4	114.6	114.2	0.81	115.1	114.1	0.70
Mean	(±6.2)	(±3.5)	(±7.7)		(±4.8)	(+6.7)	
(±SD)	(n=33)	(n=14)	(n=19)		(n=8)	(n=25)	
	Recorded as normal (n=2)						
	Recorded as high (n=1)						
Ammonia	32.3	28.8	39.5	0.35	46.0	32.3	0.60
Median	(0.0-261.6)	(5.0-93.0)	(0.0-261.6)		(13.0-104.0)	(0.0-261.6)	
(range)	(n=38)	(n=14)	(n=24)		(n=6)	(n=32)	
	Recorded as within normal limits (n=6)						
	Recorded as high (n=1)						

Glucose	5.3 (1.1-11.1)	5.5 (2.4-7.2)	5.2 (1.1-11.1)	0.40	5.8 (3.9-7.2)	5.2 (1.1-11.1)	0.13
Median (range)	(n=50)	(n=20)	(n=30)		(n=10)	(n=40)	
	Recorded as normal (n=2)						

615

616 **Table 2:** Results of univariable regression analysis of variables potentially associated with
617 survival to 30 days.

618 **Abbreviations:** LEV; levetiracetam.

Variable	Category	n,	%	Survivors (n)	Non-survivors (n)	P value
Center						0.48
Breed	Mixed breed	18	19.4	4	18	0.98
	Yorkshire terrier	15	16.1	7	8	
	Bichon Frise	12	12.9	6	6	
	Shih Tzu	8	8.6	1	7	
	Maltese terrier	6	6.5	1	5	
	Pug	9	9.7	3	6	

	Miniature Schnauzer	5	5.4	2	3	
	Jack Russell terrier	6	6.5	2	4	
	Dachshund	3	3.2	0	3	
	Chihuahua	4	4.3	1	3	
	West Highland White terrier	2	2.2	1	1	
	Norfolk terrier	1	1.1	1	0	
	Border terrier	1	1.1	1	0	
	Brussels Griffon	1	1.1	0	1	
	Coton De Tulear	1	1.1	0	1	
	Setter	1	1.1	0	1	
Sex	Male entire	19	20.4	6	13	0.64
	Male neutered	28	30.1	6	22	
	Female entire	13	14.0	5	8	
	Female spayed	31	33.3	12	19	
	Unspecified female	2	2.2	1	1	

Age (months)	Median (range)	34	(5-124)	34.5 (5-64)	34 (6-124)	0.15
Weight (kg)	Median (range)	6	(1.4-21.0)	6.0 (1.4-8.9)	6.0 (1.8-21.0)	0.16
Shunt morphology	Portocaval	67	72.0	24	43	0.99
	Portoazygous	16	17.2	6	10	
	Portophrenic	6	6.5	0	6	
	Unspecified	4	4.3	0	4	
Concurrent/historical conditions	Yes	27	29.0	9	18	0.89
	No	66	71.0	21	45	
Preoperative neurologic signs	Yes	73	78.5	27	46	0.07
	No	20	21.5	3	17	

Preoperative seizures	Yes	16	17.2	12	4	0.0003
	No	77	82.8	18	59	
Preoperative antimicrobial(s) for minimum of one week	Yes	78	83.9	29	49	0.18
	No	13	13.9	1	12	
	Unknown	2	2.2	0	2	
Preoperative lactulose for minimum of one week	Yes	81	87.1	30	51	0.99
	No	10	10.7	0	10	
	Unknown	2	2.2	0	2	
Prophylactic LEV	LEV-	43	46.2	15	28	0.2
	LEV1	22	23.7	10	12	

	LEV2	25	26.9	4	21	
	LEV3	3	3.2	1	2	
Year of surgery	2005	2	2.2	0	2	0.94
	2006	3	3.2	2	1	
	2007	1	1.1	0	1	
	2008	5	5.4	1	4	
	2009	2	2.2	0	2	
	2010	10	10.8	6	4	
	2011	10	10.8	3	7	
	2012	14	15.1	5	9	
	2013	12	12.9	4	8	
	2014	6	6.5	1	5	
	2015	12	12.9	3	9	
	2016	12	12.9	3	9	
	2017	3	3.2	1	2	

	2018	1	1.1	1	0	
Surgery from January 1st 2012 onwards	Yes	60	64.5	18	42	0.53
	No	33	35.5	12	21	
Method of shunt attenuation	Suture ligation	23	24.7	6	17	0.52
	Thin film banding	36	38.7	10	26	
	Ameroid ring constrictor	33	35.5	14	19	
	Suture ligation and thin film banding	1	1.1	0	1	
Degree of intraoperative attenuation	None	49	52.7	17	32	0.87
	Partial	24	25.8	7	17	
	Complete	20	21.5	6	14	

Type of seizures	Generalized	76	81.7	16	60	<0.0001
	Focal only	17	18.3	14	3	

619

620 **Table 3:** Results of univariable analysis of drugs administered as part of treatment of PAS.

621 **Abbreviations:** CRI: continuous rate infusion.

Variable	Category	n,	%	Survivors (n)	Non- survivors (n)	P value
Propofol CRI	Yes	49	52.7	12	37	0.21
	No	43	46.2	18	25	
	Unknown	1	1.1	0	1	
Alfaxalone CRI	Yes	3	3.2	0	3	1.0
	No	89	95.7	30	59	
	Unknown	1	1.1	0	1	
Mannitol	Yes	16	17.2	3	13	0.44
	No	76	81.7	27	49	
	Unknown	1	1.1	0	1	
Benzodiazepine(s)	Yes	45	48.4	11	34	0.27
	No	47	50.5	19	28	

	Unknown	1	1.1	0	1	
Levetiracetam	Yes	64	68.8	22	42	0.52
	No	29	31.2	8	21	
Phenobarbital	Yes	55	59.1	16	39	0.68
	No	37	39.8	14	23	
	Unknown	1	1.1	0	1	
Potassium bromide	Yes	13	14.0	7	6	0.23
	No	79	85.0	23	56	
	Unknown	1	1.1	0	1	
Alpha-2 agonist	Yes	8	8.6	4	4	0.56
	No	84	90.3	26	58	
	Unknown	1	1.1	0	1	
Gabapentin/pregabalin	Yes	4	4.3	2	2	0.45
	No	88	94.6	28	60	
	Unknown	1	1.1	0	1	
Flumazenil	Yes	2	2.2	2	0	0.98
	No	91	97.8	28	63	
	Unknown	1	1.1	0	1	

Complication during treatment of post-attenuation seizures	Yes	16	17.2	2	14	0.08
	No	77	82.8	28	49	

622

623 **Table 4:** Results of multivariable logistic regression model assessing relationship with
624 outcome of survival to 30 days.

Variable	Category	Odds Ratio	95% CI	P-value
Preoperative seizures	Yes	7.6	1.9-30.3	0.004
	No	Ref		
Type of PAS	Focal only	14.4	3.4-60.2	0.0003
	Generalized +/- focal	Ref		

625

626 **Table 5:** Reason for euthanasia, cause of natural death and complications during treatment of
627 post-attenuation seizures. *Not recorded if died or euthanized (n=3), †Not recorded if died or
628 euthanized (n=3).

Cause of natural death*	<ul style="list-style-type: none"> ▪ Cardiorespiratory arrest (n=5) ▪ Aspiration pneumonia (n=1) ▪ Suspect cerebrocortical necrosis secondary to severe hyponatremia and hyperchloremia (n=1) ▪ Spontaneous death (n=1)
--------------------------------	---

	<ul style="list-style-type: none"> ▪ Heart failure, pulmonary edema (n=1)
Reason for euthanasia†	<ul style="list-style-type: none"> ▪ Uncontrolled or recurrent seizures (n=24) ▪ Persistent seizures and poor prognosis (n=8) ▪ Uncontrolled seizures +/- financial limitations to ascertain if seizures would eventually cease (n=5) ▪ Respiratory arrest (n=2) ▪ Poor mentation (n=1) ▪ Blind, unable to stand, welfare concerns (n=1) ▪ Disorientated, vocalizing and non-responsive (n=1) ▪ Seizures, suspected aspiration pneumonia (n=1) ▪ Seizures, hypoventilation and poor prognosis (n=1) ▪ Seizures, unresponsive and fulminant liver failure (n=1) ▪ Suspected portal hypertension (n=1) ▪ Aspiration pneumonia (n=1) ▪ Uncontrolled neurologic signs (n=1) ▪ Uncontrolled seizures and pulmonary edema (n=1) ▪ Unsuccessful reanimation (n=1) ▪ Seizures, coma (n=1)
Complications during treatment of post-attenuation seizures	<ul style="list-style-type: none"> ▪ Aspiration pneumonia (n=4) ▪ Pyrexia, respiratory arrest and aspiration pneumonia (n=1) ▪ Aspiration pneumonia and suspect thromboembolic event (n=1)

	<ul style="list-style-type: none">▪ Acute renal failure, cardiogenic edema and pneumonia (n=1)▪ Repeated respiratory arrest (n=1)▪ Hypoventilation requiring mechanical ventilation (n=1)▪ Hypoventilation requiring mechanical ventilation, suspected vagal event (hypertension and tachycardia), respiratory arrest (n=1)▪ Fulminant liver failure (n=1)▪ Hyperthermia, tachycardia, hematochezia suspected related to portal hypertension (no mesenteric congestion at revision coeliotomy) (n=1)▪ Sepsis suspected to be associated with gastrostomy tube (n=1)▪ Sepsis, systemic inflammatory response syndrome, disseminated intravascular coagulation, suspect pneumonia, requirement for mechanical ventilation (n=1)▪ Pulmonary edema (n=1)▪ Pulmonary edema, hypothermia and hyperthermia (n=1)
--	--